(Q41369754)

30 September 2017

title

Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis (English)

1 reference

30 September 2017

30

1 reference

30 September 2017

Giacomo Lus

18

0 references

Carla Tortorella

Carla Tortorella

27

0 references

Paola Cavalla

Paola Cavalla

23

0 references

Francesco Corea

Francesco Corea

21

0 references

Antonio Bertolotto

Antonio Bertolotto

12

0 references

Alessandra Lugaresi

Alessandra Lugaresi

8

0 references

Maria Giovanna Marrosu

Maria Giovanna Marrosu

10

0 references

Maria Trojano

Maria Trojano

33

0 references

Maria Pia Amato

Maria Pia Amato

11

0 references

Giancarlo Comi

32

Giancarlo Comi

1 reference

30 September 2017

5

Angelo Ghezzi

1 reference

30 September 2017

13

Roberto Bergamaschi

1 reference

30 September 2017

16

Gioacchino Tedeschi

1 reference

30 September 2017

3

Carlo Pozzilli

1 reference

30 September 2017

25

Mariaemma Rodegher

1 reference

30 September 2017

7

Francesco Patti

1 reference

30 September 2017

26

Damiano Paolicelli

1 reference

30 September 2017

1

Pietro Iaffaldano

1 reference

30 September 2017

2

Giuseppe Lucisano

1 reference

30 September 2017

15

Gabriella Coniglio

1 reference

30 September 2017

6

Enrico Millefiorini

1 reference

30 September 2017

Giovanni Bosco Zimatore

9

Giovanni Bosco Zimatore

1 reference

30 September 2017

17

Patrizia Sola

1 reference

30 September 2017

29

Luca Prosperini

1 reference

30 September 2017

31

Damiano Baroncini

1 reference

30 September 2017

14

Franco Granella

1 reference

30 September 2017

19

Maria Teresa Ferrò

1 reference

30 September 2017

20

Gerardo Iuliano

1 reference

30 September 2017

28

Vito Lepore

1 reference

30 September 2017

author name string

Vincenzo Brescia Morra

4

1 reference

30 September 2017

Alessandra Protti

22

1 reference

30 September 2017

Angelica Guareschi

24

1 reference

30 September 2017

Italian iMed-Web database

34

1 reference

30 September 2017

language of work or name

English

0 references

publication date

11 September 2015

1 reference

30 September 2017

1 reference

30 September 2017

volume

138

1 reference

30 September 2017

issue

Pt 11

1 reference

30 September 2017

page(s)

3275-3286

1 reference

A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study.

30 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWV260

Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWV260

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWV260

Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWV260

Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWV260

Relapses in patients treated with fingolimod after previous exposure to natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWV260

MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWV260

De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWV260

Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWV260

Fingolimod after natalizumab and the risk of short-term relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWV260

Course of relapsing-remitting multiple sclerosis before, during and after natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWV260

Natalizumab drug holiday in multiple sclerosis: poorly tolerated

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWV260

Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWV260

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWV260

Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWV260

Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWV260

Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWV260

Estimating causal effects of public health education campaigns using propensity score methodology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWV260

21 January 2018

Identifiers

DOI

10.1093/BRAIN/AWV260

1 reference

30 September 2017

1 reference